Literature DB >> 10377151

CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice.

V Julia1, N Glaichenhaus.   

Abstract

Leishmania major induces the rapid production of interleukin-4 (IL-4) in both susceptible BALB/c and resistant B10.D2 mice. In both strains, IL-4 is produced by T cells which react to the parasite LACK (for Leishmania homolog of the receptor for activated C kinase) antigen. The rapid production of IL-4 in B10.D2 mice does not confer susceptibility but results in increased parasite burdens.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10377151      PMCID： PMC116556     

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  26 in total

1.  Early IL-4 production does not predict susceptibility to Leishmania major.

Authors:  P Scott; A Eaton; W C Gause; X di Zhou; B Hondowicz
Journal:  Exp Parasitol       Date:  1996-11       Impact factor: 2.011

2.  Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.

Authors:  T F Gajewski; M Pinnas; T Wong; F W Fitch
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

3.  T cell genetic background determines maintenance of IL-12 signaling: effects on BALB/c and B10.D2 T helper cell type 1 phenotype development.

Authors:  M L Güler; N G Jacobson; U Gubler; K M Murphy
Journal:  J Immunol       Date:  1997-08-15       Impact factor: 5.422

4.  Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice.

Authors:  A M Beebe; S Mauze; N J Schork; R L Coffman
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

5.  Constructing polycompetitor cDNAs for quantitative PCR.

Authors:  S L Reiner; S Zheng; D B Corry; R M Locksley
Journal:  J Immunol Methods       Date:  1993-09-27       Impact factor: 2.303

6.  Interleukin-4 transgenic mice of resistant background are susceptible to Leishmania major infection.

Authors:  L M Leal; D W Moss; R Kuhn; W Müller; F Y Liew
Journal:  Eur J Immunol       Date:  1993-02       Impact factor: 5.532

7.  The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.

Authors:  R A Seder; W E Paul; M M Davis; B Fazekas de St Groth
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

8.  A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice.

Authors:  C R Gabaglia; B Pedersen; M Hitt; N Burdin; E E Sercarz; F L Graham; J Gauldie; T A Braciak
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

9.  Resistance to Leishmania major is linked to the H2 region on chromosome 17 and to chromosome 9.

Authors:  L J Roberts; T M Baldwin; J M Curtis; E Handman; S J Foote
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

10.  Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.

Authors:  M D Sadick; F P Heinzel; B J Holaday; R T Pu; R S Dawkins; R M Locksley
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307
View more
  13 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  T cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice.

Authors:  S Schilling; N Glaichenhaus
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  The levels and patterns of cytokines produced by CD4 T lymphocytes of BALB/c mice infected with Leishmania major by inoculation into the ear dermis depend on the infectiousness and size of the inoculum.

Authors:  Thierry Lang; Nathalie Courret; Jean-Hervé Colle; Geneviève Milon; Jean-Claude Antoine
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

5.  The Leishmania major LACK antigen with an immunodominant epitope at amino acids 156 to 173 is not required for early Th2 development in BALB/c mice.

Authors:  Ben L Kelly; Richard M Locksley
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

6.  Inbred strains derived from feral mice reveal new pathogenic mechanisms of experimental leishmaniasis due to Leishmania major.

Authors:  Besma E C Babay; Hechmi Louzir; Chahnaz Kebaïer; Samir Boubaker; Koussay Dellagi; Pierre-André Cazenave
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions.

Authors:  Dong Liu; Chahnaz Kebaier; Nazzy Pakpour; Althea A Capul; Stephen M Beverley; Phillip Scott; Jude E Uzonna
Journal:  Infect Immun       Date:  2009-06-01       Impact factor: 3.441

8.  Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.

Authors:  Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Fernando Aécio Amorim Carvalho; Karina Figueiredo Chaves; Kadima Nayara Teixeira; Rafaela Chitarra Rodrigues; Hugues Charest; Greg Matlashewski; Ricardo Tostes Gazzinelli; Ana Paula Fernandes
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

9.  Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains.

Authors:  Fouad Benhnini; Mehdi Chenik; Dhafer Laouini; Hechmi Louzir; Pierre André Cazenave; Koussay Dellagi
Journal:  Clin Vaccine Immunol       Date:  2009-09-02

10.  Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.

Authors:  Katherine Kedzierska; Joan M Curtis; Sophie A Valkenburg; Lauren A Hatton; Hiu Kiu; Peter C Doherty; Lukasz Kedzierski
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.